Skip to main content

Table 1 Patient characteristics

From: Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

Characteristics Patients
Entered n = 54
Age median (years) (range) 46 years (range 25 – 73 y)
Estrogen receptor/progesterone receptor positive 23/15
HERcepTest+++/FISH+ 51/3
primary metastatic disease 12 (22.2%)
Metastatic sites median (range) 3 (range 1–7 sites)
   Lung 22
   Liver 29
   Bones 30
   Lymph nodes 22
   Soft tissue 36
   Skin 11
   Brain 11
   Others 3
More than one metastatic site 48 (88.8%)
Adjuvant chemotherapy 31 (57.4%)
   Adjuvant docetaxel 13
   Adjuvant anthracyclines 19
Adjuvant endocrine therapy 15 (27.7%)
Palliative endocrine therapy 20 (37%)
1st line combination n = 54 pts
   Vinorelbine 35
   Capecitabine 2
   Gemcitabine 0
   Docetaxel 12
   Platinum derivatives 0
   Others 5
2nd line combination n = 54 pts
   Vinorelbine 15
   Capecitabine 11
   Gemcitabine 9
   Docetaxel 11
   Platinum derivatives 0
   Others 8
Beyond 2nd line combination n = 60 therapies
   Vinorelbine 6
   Capecitabine 14
   Gemcitabine 14
   Docetaxel 4
   Platinum derivatives 11
   Others 11